Company Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Dr. Christopher J. Kirk Ph.D. |
Contact Details
Address: 4000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650-822-5600 |
| Website | kezarlifesciences.com |
Stock Details
| Ticker Symbol | KZR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645666 |
| CUSIP Number | 49372L100 |
| ISIN Number | US49372L1008 |
| Employer ID | 47-3366145 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, Chief Executive Officer and Director |
| John Franklin Fowler | Co-Founder and Director |
| Dr. Jack Taunton Ph.D. | Co-Founder |
| Marc L. Belsky | Chief Financial Officer and Secretary |
| Gitanjali Jain | Vice President of Investor Relations and External Affairs |
| Mark Schiller | Chief Legal Officer |
| Dr. Neel K. Anand Ph.D. | Senior Vice President of Research and Drug Discovery |
| Dr. Nick Mordwinkin Ph.D., Pharm.D. | Chief Business Officer and Head of Strategy |
| Zung To | Senior Vice President of Clinical Development |
| Pattie Chiang | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 22, 2024 | 424B5 | Filing |
| Mar 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 14, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |